Home > Boards > US Listed > Biotechs > Vascular Biogenics Ltd. (VBLT)

The Feurstein tweets(and others) over the weekend scared

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
davidal66 Member Profile
 
Followed By 8
Posts 2,058
Boards Moderated 0
Alias Born 07/19/06
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/17/2019 5:22:27 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/17/2019 5:21:38 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/15/2019 7:03:28 AM
VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15 GlobeNewswire Inc. - 5/6/2019 8:00:00 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/28/2019 7:03:42 AM
VBL Therapeutics to Present at Upcoming Conferences in April GlobeNewswire Inc. - 3/25/2019 8:00:00 AM
VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microe... GlobeNewswire Inc. - 3/19/2019 7:00:00 AM
VBL Therapeutics to Report Fiscal Year 2018 Financial Results on March 28 GlobeNewswire Inc. - 3/14/2019 8:00:00 AM
VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer on March 18 GlobeNewswire Inc. - 3/11/2019 8:00:00 AM
VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Ar... GlobeNewswire Inc. - 2/26/2019 8:00:00 AM
VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority GlobeNewswire Inc. - 2/20/2019 8:00:00 AM
VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26 GlobeNewswire Inc. - 2/19/2019 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 1:46:23 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/17/2019 11:50:07 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/7/2019 7:10:58 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 12/18/2018 4:07:59 PM
VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28 GlobeNewswire Inc. - 11/21/2018 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/20/2018 7:02:14 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/16/2018 8:48:02 AM
VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Ne... GlobeNewswire Inc. - 11/16/2018 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/23/2018 8:17:48 AM
Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB... GlobeNewswire Inc. - 10/23/2018 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/15/2018 8:17:04 AM
Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple... GlobeNewswire Inc. - 10/11/2018 7:00:00 AM
VBL Therapeutics to Present at Upcoming Conferences in October GlobeNewswire Inc. - 9/17/2018 8:00:00 AM
davidal66   Monday, 06/13/16 11:05:31 AM
Re: None
Post # of 1987 
The Feurstein tweets(and others) over the weekend scared me concerning the ovarian cancer data set presented. He talked about the censoring of patients in the ovarian cancer data set left of the median. He and others biotech guys on twitter also raised my eyebrow on the rGBM data set presented.... Scared my weak hands. Nice gain of 10K from my entering point. I might be back if I can counter their logic, but out of the stock for now. If you look at the KM plot on the ovarian data presented at ASCO, you'll notice a lot of censoring of patients left of the 800 day mark. Feurstein's argument is this makes the OS numbers suspect.

More important, as to the rGBM phase II trial. If you look at the initial poster at ASCO from the phase I/11 rGBM trial, the combination arm initially yielded 12 months OS, but then a year later, up to 15 months. There was also a changing of the statistical measurements of the trial, changing of the primary endpoint, and other oddities I've learned over the weekend that freaked me out.

I may be back into the stock when I can learn more that might counter this bearish thesis. David

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist